In summary, our findings determined the crucial function of FoxO3a in mCRC cetuximab resistance through regulating of c-Myc downstream metabolic associated genes, suggesting that FoxO3a might be a novel biomarker and therapeutic target in colorectal cancer therapy. The gene discussed is FOXO3; the disease is colorectal cancer.